Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 2, 2009, Pages 181-187

  Grocott, Rachel ^a  

^a Pharmaceutical Management Agency   (New Zealand)

Author keywords

Budget; budget management; Cost utility analysis; Economic analysis; Expenditure management; Programme Budgeting Marginal Analysis; Relative cost effectiveness; Tender; Threshold; Value for money threshold value for money

Indexed keywords

BUDGET; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE COST; NEW ZEALAND; PHARMACY; PROGRAM BUDGETING MARGINAL ANALYSIS; RESOURCE MANAGEMENT; REVIEW; STRATEGIC PLANNING; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; RISK MANAGEMENT; STATISTICS;

BUDGETS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; NEW ZEALAND; PHARMACEUTICAL SERVICES; RISK SHARING, FINANCIAL;

EID: 68349135840     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.2     Document Type: Review

References (13)

1. Braae R, McNee W, Moore D. Managing pharmaceutical expenditure while increasing access. The Pharmaceutical Management Agency (PHARMAC) experience. Pharmacoeconomics 16(6), 649-660 (1999).
2. Claxton K, Briggs A, Buxton MJ et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 336(7638), 251-254 (2008).
3. Birch S, Gafni A. The 'NICE' approach to technology assessment: an economics perspective. Health Care Manag. Sci. 7(1), 35-41 (2004).
4. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA 298(2), 221-224 (2007).
5. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 24(11), 1121-1131 (2006).
6. Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics 24(11), 1133-1142 (2006).
7. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91-98 (2008).
8. Appleby J, Devlin N, Parkin D. NICE's cost-effectiveness threshold. BMJ 335(7616), 358-359 (2007).
9. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26(9), 733-744 (2008).
10. Cohen J, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 25(9), 727-734 (2007).
11. Brougham M, Metcalfe S, McNee W. Our advice? Get a budget! Healthc. Pap. 3(1), 83-85; discussion 87-94 (2002).
12. Grocott R, Metcalfe S. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. NZ Med. J. 118(1223), U1690 (2005).
13. Grocott R, Schoeler R, Priest V et al. Prescription for Pharmacoeconomic Analysis - Methods for Cost-Utility Analysis. Version 2. Pharmaceutical Management Agency, PHARMAC, Wellington, New Zealand(2007).